Navigation Links
bioRASI Completes Acquisition of Ukrainian CRO
Date:3/28/2013

Aventura, FL (PRWEB) March 28, 2013

bioRASI, a full service, global Contract Research Organization (CRO), announced today that it has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG was established in 2004 and has been conducting clinical studies in an extensive range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.

“We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure,” explained Dr. Boris Reznik, Chairman of bioRASI. “This acquisition enhances bioRASI’s global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs.”

The acquisition of SCRG addresses the ever-increasing demand for optimizing global clinical trials and builds upon bioRASI’s already commanding presence throughout Eastern Europe.

“While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI,” explained Dr. Veklych, SCRG’s Executive Director. “An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI’s winning team.”    

About bioRASI
bioRASI is an award-winning Full Service Global CRO providing clinical development services that optimize its sponsors’ scientific, clinical, and business results. bioRASI facilitates obtaining global marketing approval for drugs, biotherapeutics, and medical devices by delivering high quality regulatory and clinical strategies, solutions and services. The Company's unique access to the largest facilities and patient populations worldwide saves clients critical time. bioRASI's services include program optimization, project management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI is headquartered in Aventura, FL and has regional offices and operations across North America and around the world.

Click here for a copy of our White Paper Series.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10578507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Novira Therapeutics Completes $25 Million Series A Financing
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Amarantus Completes Name Change and CUSIP Change
4. Advanced Cell Diagnostics Completes $12 Million Series B Financing
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
7. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
8. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
9. China Integrated Energy Inc. Completes Independent Investigation
10. Oxford Finance Completes $271.4 Million Securitization Transaction
11. inVentiv Health Completes Acquisition of Kforce Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):